- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05093166
Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure (HOLOUR)
Prospective, Open-label, Uncontrolled Pilot Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Oral Mucosa Grafts for Urethral Reconstruction in Patients Due to Hypospadias Treatment Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Holour is a prospective, open-label, uncontrolled pilot clinical trial phase i/ii. The aim of this clinical trial is to perform a tissue engineering therapy to assess the safety (at 3 and 12 months) and efficacy (at 12 months) of the autologous treatment.
Patients will be screened according to the study inclusion and exclusion criteria and will be candidate for the treatment if all eligibility criteria are met. Up to 8 patients will be treated by means of autologous cultured oral mucosa grafts containing oral mucosa stem cells. Holour is produced by ex vivo expansion of cells obtained from oral mucosa biopsy collected from patient. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted. Holour administration will be planned according to the procedures and the need of the patient.
The entire procedure envisages the following steps:
- Oral mucosa biopsy to manufacture autologous grafts of Holour.
Penile urethroplasty in two stages:
- First stage: application of holour on the wound bed prepared according to standard surgery.
- Second stage: penis reconstruction according to standard surgical procedure. The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics.
The treatment includes a single administration of Holour; in case of "failure" of the first procedure eligible patients can undergo to a second implantation.
Three months after the transplantation, primary endpoint will be evaluated by the investigator. The study completion will be reached when 1 year (secondary endpoint) of follow-up after the last transplant in the last patient will be accomplished.
The end of the trial is defined as the last visit of the last patient after the last treatment if any.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20122
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent prior to any study-related procedures (Caregivers); Patients whose parents/legal representatives have been thoroughly informed of the aim of the study procedures and provided signed and dated written informed consent;
- Male patients between 5 and 17 years old (less than 18 years old);
- Need for urethroplasty in failed hypospadias treatment;
- Hypospadias complications shown by clinical evaluation, uroflowmetry with post-micturition residual evaluation and/or retrograde urethrography and/or urethroscopy;
- Uroflowmetry rate: Uroflowmetry with a plateau-shaped curve and low qmax according to paediatric uroflow normograms;
- Absence of other contraindications to HOLOUR implantation based on investigator's judgement;
- A cooperative attitude to follow up the study procedures (Caregivers in case of minors).
Exclusion Criteria:
- Known or suspected intolerances against anaesthesia;
- Bad general condition (ECOG index >2);
- Clinical and/or laboratory signs of acute systemic infections and/or severe inflammation at the time of screening. Patient can be re-screened after appropriate treatment;
- Severe systemic disease (i.e. uncompensated diabetes);
- Stenosis or retraction secondary to medical conditions other than hypospadias failure (i.e. radiotherapy, lichen sclerosis, etc…);
Allergy, sensitivity or intolerance to drugs or excipients (hypersensitivity to any of the excipients listed in Investigator's brochure or in this protocol):
- Transport medium (Dulbecco's Modified Eagles Medium supplemented with L-glutamine)
- Fibrin support;
- Contraindications to the post- treatment local or systemic antibiotics and/or corticosteroids;
- UTI or urine culture positive requiring a re-screening of patient;
- Contraindications to undergo extensive surgical procedures;
- Clinically significant or unstable concurrent disease or other clinical contraindications to stem cell implantation based on investigator's judegment or other concomitant medical conditions affecting grafting procedure;
- Patients and parents/tutor unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study procedures and treatments;
- Participation in another clinical trial where conventional investigational drug was received less than 1 months prior to screening visit;
- Patients who received surgical procedure within 6 months prior to screening visit;
- Anaesthesia or severe hypoesthesia of the area;
- Diagnosis of local or systemic neoplastic disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Urethral reduced functionality and/or lesions due to previous hypospadias treatment failure
The first step consists in a small oral mucosa biopsy collection by surgeon under general anaesthesia. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted. The treatment for urethra reconstruction required a two stage urethroplasty:
The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics. |
The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and percentage of patients experiencing AESI
Time Frame: 3 months after treatment
|
To demonstrate the safety of Holour in terms of AESI (persistent fever, infections)
|
3 months after treatment
|
Number and percentage of patients experiencing ADRs
Time Frame: 3 months after treatment
|
To demonstrate the safety of Holour in terms of ADRs
|
3 months after treatment
|
Number and percentage of patients experiencing SAEs
Time Frame: 3 months after treatment
|
To demonstrate the safety of Holour in terms of SAEs
|
3 months after treatment
|
Number and percentage of patients experiencing Serious ADRs
Time Frame: 3 months after treatment
|
To demonstrate the safety of Holour in terms of Serious ADRs
|
3 months after treatment
|
Number and percentage of patients experiencing AESI
Time Frame: 12 months after treatment
|
To demonstrate the safety of Holour in terms of AESI (persistent fever, infections)
|
12 months after treatment
|
Number and percentage of patients experiencing ADRs
Time Frame: 12 months after treatment
|
To demonstrate the safety of Holour in terms of AESI ADRs
|
12 months after treatment
|
Number and percentage of patients experiencing SAEs
Time Frame: 12 months after treatment
|
To demonstrate the safety of Holour in terms of SAEs
|
12 months after treatment
|
Number and percentage of patients experiencing Serious ADRs
Time Frame: 12 months after treatment
|
To demonstrate the safety of Holour in terms of Serious ADRs
|
12 months after treatment
|
Number of patients with implantation success
Time Frame: 12 months after treatment
|
Implantation success is defined on the basis of the degree of clinical (no lesions, no significant retractions) epithelial stability on the transplanted area.
The degree of epithelial stability will be evaluated by visual inspection, cistouretrography, uretroscophy and checked for evaluating reepithelialization, erosions, infection, etc. and documented with photos with measures.
|
12 months after treatment
|
percentage of patients with implantation success
Time Frame: 12 months after treatment
|
Implantation success is defined on the basis of the degree of clinical (no lesions, no significant retractions) epithelial stability on the transplanted area.
The degree of epithelial stability will be evaluated by visual inspection, cistouretrography, uretroscophy and checked for evaluating reepithelialization, erosions, infection, etc. and documented with photos with measures.
|
12 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with the treatment efficacy after Holour implantation and surgical reconstruction
Time Frame: up to 1 year after implantation
|
Regeneration of a clinically normal appearing urethra epithelium with absence of detectable erosions/retractions and Clinical functionality (uroflowmetry) after the second step (urethral reconstruction) of transplant.
|
up to 1 year after implantation
|
Evaluation of the percentage of re-epithelialization
Time Frame: up to 1 year after implantation
|
Evaluation of the percentage of re-epithelialization
|
up to 1 year after implantation
|
Evaluation of the clinical epithelial stability on the transplanted area by visual inspections
Time Frame: up to 1 year after implantation
|
Evaluation of the regeneration of a clinically normal appearing epithelium with absence of detectable erosions/retractions
|
up to 1 year after implantation
|
Evaluation of scar retraction presence
Time Frame: up to 1 year after implantation
|
Evaluation of the penile retraction due to presence/absence of scars
|
up to 1 year after implantation
|
Evaluation of uroflowmetry rate
Time Frame: From 3 to 12 months after the treatment
|
Evaluation of the change of uroflowmetry compared to the baseline value with change of the curve shape and significant increase of the qmax flow rate;
|
From 3 to 12 months after the treatment
|
Evaluation of the post-void residual volume through uroflowmetry
Time Frame: From 3 to 12 months after the treatment
|
Evaluation of the change of the post-void residual compared to the baseline
|
From 3 to 12 months after the treatment
|
Evaluation of the presence and severity of surgical complications
Time Frame: up to 1 year after implantation
|
Presence and severity of surgical complications using the Clavien Dindo scale with the classification into 5 grades (I, II, III, IV and V from no need for clinical intervention to the death of the patient)
|
up to 1 year after implantation
|
Evaluation of the adeverse events in terms of SAEs, AESI, ADR Serious ADRs,
Time Frame: up to 1 year after implantation
|
Evaluation of the adeverse events in terms of SAEs, AESI, ADR Serious ADRs,
|
up to 1 year after implantation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Graziella Pellegrini, Professor, Holostem Terapie Avanzate s.r.l.
- Principal Investigator: Gianantonio Manzoni, MD, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HTA-HUR-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypospadias
-
Albany Medical CollegeEnrolling by invitation
-
Sohag UniversityCompletedCosmotic Outcome of Distal Penile Hypospidias Repair Using Stitch by Stitch Glanuloplasty Versus TIPDistal Penile HypospadiasEgypt
-
Yonsei UniversityCompletedPediatric Patients Undergoing Hypospadias SurgeryKorea, Republic of
-
Assiut UniversityNot yet recruiting
-
dr. Muhammad Abdelhafez Mahmoud, MDCompletedChordee | Hypospadias, Penoscrotal
-
Tanta UniversityUnknownPediatric | Dexmedetomidine Infusion | Hypospadias Repair SurgeryEgypt
-
Isfahan University of Medical SciencesUnknown
-
Mansoura UniversityCompleted164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal BlockEgypt
-
Nemours Children's ClinicCompletedHypospadias and EpispadiasUnited States
Clinical Trials on "Ex vivo" expanded autologous human oral epithelium containing stem cells
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States
-
King Edward Medical UniversityUnknownLipodystrophy | Craniofacial Microsomia | Mixed Connective Tissue Disease | Romberg's Disease
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Juvenile Diabetes...CompletedType 1 Diabetes MellitusUnited States
-
Central Hospital, Nancy, FranceCompleted
-
University of AlbertaJuvenile Diabetes Research Foundation; Diabetes Research Institute Foundation; Alberta Diabetes Institute and other collaboratorsActive, not recruiting
-
Clinica Universidad de Navarra, Universidad de...Spanish National Health SystemUnknownFollicular Lymphoma | Follicular Non-Hodgkin´s Lymphoma | Autologous Effector LymphocytesSpain
-
University of FloridaUnited States Department of Defense; AM Rosen FoundationRecruitingGlioblastoma | Glioblastoma MultiformeUnited States
-
Mesoblast, Inc.No longer availableGraft-Versus-Host DiseaseUnited States
-
University of California, Los AngelesRecruitingAdenosine Deaminase Severe Combined Immune DeficiencyUnited States
-
Mesoblast, Inc.Juvenile Diabetes Research FoundationCompletedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent | Juvenile DiabetesUnited States